Synedgen


Developer of glycomics-based regenerative therapeutics focused on restoring mucosal barrier function. The company advances orally delivered and topical therapeutics from preclinical models into clinic-ready assets, operates a platform for targeted glycomics discovery, reports clinical and preclinical efficacy data (including GI mucosal repair and an oral rinse for xerostomia), and holds funded grants and patent protection for its programs.

Industries

Biotechnology
Health Care
Health Diagnostics
Medical Device
Pharmaceutical
Therapeutics
Biotechnology Research

Nr. of Employees

small (1-50)

Synedgen

Claremont, California, United States


Patents

Methods for treatment or prevention of damage resulting from radiation, trauma or shock

US-12594296-B2

View Details

Compositions and methods of use thereof

US-12533375-B2

View Details

Compositions and methods of use thereof

US-12533374-B2

View Details

Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds

US-12465616-B2

View Details

Methods for treatment or prevention of damage resulting from radiation, trauma or shock

US-11975018-B2

View Details

Compositions and methods of use thereof

US-11957707-B2

View Details
View All Patents

Products

MIIST305

Clinic-ready, orally delivered therapeutic candidate developed to repair gastrointestinal mucosal injury, restore GI function, and reduce inflammation; supported by preclinical efficacy data.

Moisyn oral rinse

Oral rinse product line developed for xerostomia (dry mouth); received U.S. FDA 510(k) clearance and demonstrated symptom improvements in a clinical study.

SYGN305

Drug candidate developed for the treatment of Radiation Mucositis and Radiation Proctitis.

SYGN309

Drug candidate developed for GI Infection.

SYGN313

Drug candidate developed for both acute and chronic inflammation of the GI tract, such as Crohn’s disease and inflammatory bowel disease (IBD).

SYGN399

Drug candidate developed for Radiation Syndrome.

Expertise Areas

  • Glycomics-driven drug discovery
  • Mucosal barrier repair and regenerative therapeutics
  • Gastrointestinal (GI) therapeutic development
  • Oral care therapeutics and xerostomia treatment
  • Show More (5)

Key Technologies

  • Glycomics-based discovery
  • Oral drug formulation and delivery
  • Mucosal barrier restoration mechanisms
  • Preclinical murine models
  • Show More (3)

News & Updates

Company announced executive leadership changes naming Dr. Laura Saward CEO and Dr. Kenton Gregory CMO.

Announcement of Gut Microbes publication reporting preclinical data that MIIST305 mitigates gastrointestinal acute radiation syndrome injury in a mouse model.

Company announced the appointment of Dr. Laura Saward as Chief Scientific Officer.

Company received U.S. FDA 510(k) clearance to market Moisyn products for treatment of xerostomia.

EU patent granted covering treatment of gastrointestinal mucositis.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.